{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:45:39Z","timestamp":1791949539733,"version":"4.3.4"},"reference-count":59,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2026,6,30]]},"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1136\/jnnp-2026-338694","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T14:20:11Z","timestamp":1789395611000},"page":"992-1003","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Age and treatment class modify inflammatory risk after disease-modifying therapy discontinuation in older people with MS"],"prefix":"10.1136","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3583-8412","authenticated-orcid":false,"given":"Ren\u00e9","family":"Carvajal","sequence":"first","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"CORe, Department of Medicine, University of Melbourne; Neuroimmunology Centre, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Marcialis","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Tur","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana","family":"Otero-Romero","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Department of Preventive Medicine and Epidemiology, Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0371-3666","authenticated-orcid":false,"given":"Izanne","family":"Roos","sequence":"additional","affiliation":[{"name":"CORe, Department of Medicine, University of Melbourne; Neuroimmunology Centre, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustin","family":"Pappolla","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3402-4759","authenticated-orcid":false,"given":"Frederik","family":"Novak","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2574-0721","authenticated-orcid":false,"given":"Alvaro","family":"Cobo-Calvo","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4036-1671","authenticated-orcid":false,"given":"Helena","family":"Ari\u00f1o","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2657-5510","authenticated-orcid":false,"given":"Georgina","family":"Arrambide","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Bollo","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Casallas-Vanegas","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Castill\u00f3","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2373-6657","authenticated-orcid":false,"given":"Manuel","family":"Comabella","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e2ndida","family":"Driemeyer","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iker","family":"Elosua","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristian","family":"Fadrique","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Gal\u00e1n","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gr\u00e1valos","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delon","family":"La Puma","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariadna","family":"Masot","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana","family":"Midaglia","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Molina-Goicoechea","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0338-4797","authenticated-orcid":false,"given":"Neus","family":"Mongay-Ochoa","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breog\u00e1n","family":"Rodr\u00edguez-Acevedo","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"R\u00edo","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Tagliani","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7270-5507","authenticated-orcid":false,"given":"Angela","family":"Vidal-Jordana","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreu","family":"Vilaseca-Jolonch","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3860-5251","authenticated-orcid":false,"given":"Ana","family":"Zabalza","sequence":"additional","affiliation":[{"name":"Servei de Neurologia-Neuroimmunologia. Centre d\u2019Esclerosi M\u00faltiple de Catalunya (Cemcat), Vall d\u2019Hebron University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Pugliatti","sequence":"additional","affiliation":[{"name":"Department of Neuroscience and Rehabilitation, University of Ferrara, Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1589-2254","authenticated-orcid":false,"given":"Jaume","family":"Sastre-Garriga","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3778-1376","authenticated-orcid":false,"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[{"name":"CORe, Department of Medicine, University of Melbourne; Neuroimmunology Centre, The Royal Melbourne Hospital, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Montalban","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Faculty of Medicine, University of Vic - Central University of Catalonia, Vic, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Tintore","sequence":"additional","affiliation":[{"name":"Department of Neurology-Neuroimmunology and Multiple Sclerosis Centre of Catalonia (Cemcat), Hospital Universitari Vall d\u2019Hebron, Barcelona, Spain"},{"name":"Faculty of Medicine, University of Vic - Central University of Catalonia, Vic, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"2026101308350876000_97.11.992.1","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1007\/s00415-023-12047-9","article-title":"Increasing age of multiple sclerosis onset from 1920 to 2022: a population-based study","volume":"271","author":"Habbestad","year":"2024","journal-title":"J Neurol"},{"key":"2026101308350876000_97.11.992.2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012726"},{"key":"2026101308350876000_97.11.992.3","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awae245"},{"key":"2026101308350876000_97.11.992.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0082-z"},{"key":"2026101308350876000_97.11.992.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41583-024-00823-z"},{"key":"2026101308350876000_97.11.992.6","doi-asserted-by":"publisher","DOI":"10.1177\/1352458519866613"},{"key":"2026101308350876000_97.11.992.7","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000210305","article-title":"Age-Related Disability Outcomes After a First Demyelinating Event","volume":"104","author":"Cobo-Calvo","year":"2025","journal-title":"Neurology"},{"key":"2026101308350876000_97.11.992.8","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41582-025-01115-5","article-title":"Advancing multiple sclerosis management in older adults","volume":"21","author":"van der Walt","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"2026101308350876000_97.11.992.9","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200211","article-title":"Multiple Sclerosis, Rituximab, Hypogammaglobulinemia, and Risk of Infections","volume":"11","author":"Langer-Gould","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026101308350876000_97.11.992.10","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbih.2022.100470","article-title":"Risk of serious infections in multiple sclerosis patients by disease course and disability status: Results from a Swedish register-based study","volume":"22","author":"Brand","year":"2022","journal-title":"Brain Behav Immun Health"},{"key":"2026101308350876000_97.11.992.11","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/brain\/awae409","article-title":"De-escalating and discontinuing disease-modifying therapies in multiple sclerosis","volume":"148","author":"Androdias","year":"2025","journal-title":"Brain"},{"key":"2026101308350876000_97.11.992.12","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1177\/13524585251344792","article-title":"Should disease-modifying therapy be discontinued in older patients with stable MS after long-term clinical and radiological stability? Yes","volume":"31","author":"Androdias","year":"2025","journal-title":"Mult Scler"},{"key":"2026101308350876000_97.11.992.13","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1177\/13524585251344805","article-title":"Should disease-modifying therapy be discontinued in older patients with stable multiple sclerosis after long-term clinical and radiological stability? No","volume":"31","author":"Foong","year":"2025","journal-title":"Mult Scler"},{"key":"2026101308350876000_97.11.992.14","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1001\/jamaneurol.2024.4164","article-title":"Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical Trial","volume":"82","author":"Coerver","year":"2025","journal-title":"JAMA Neurol"},{"key":"2026101308350876000_97.11.992.15","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(23)00154-0"},{"key":"2026101308350876000_97.11.992.16","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2016-313760"},{"key":"2026101308350876000_97.11.992.17","doi-asserted-by":"crossref","first-page":"107612","DOI":"10.1016\/j.clineuro.2023.107612","article-title":"Discontinuation of disease-modifying therapy in MS patients over 60 years old and its impact on relapse rate and disease progression","volume":"225","author":"Salavisa","year":"2023","journal-title":"Clin Neurol Neurosurg"},{"key":"2026101308350876000_97.11.992.18","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1177\/1352458518765656","article-title":"Discontinuation of disease-modifying therapy in patients with multiple sclerosis over age 60","volume":"25","author":"Hua","year":"2019","journal-title":"Mult Scler"},{"key":"2026101308350876000_97.11.992.19","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1177\/1352458516675751","article-title":"Discontinuation of disease-modifying therapies in multiple sclerosis - Clinical outcome and prognostic factors","volume":"23","author":"Bsteh","year":"2017","journal-title":"Mult Scler"},{"key":"2026101308350876000_97.11.992.20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.7224\/1537-2073.2015-032","article-title":"Stopping Disease-Modifying Therapy in Nonrelapsing Multiple Sclerosis: Experience from a Clinical Practice","volume":"19","author":"Birnbaum","year":"2017","journal-title":"Int J MS Care"},{"key":"2026101308350876000_97.11.992.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.07.021"},{"key":"2026101308350876000_97.11.992.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-10029-9"},{"key":"2026101308350876000_97.11.992.23","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1111\/ene.14705","article-title":"Quantifying the risk of disease reactivation after interferon and glatiramer acetate discontinuation in multiple sclerosis: The VIAADISC score","volume":"28","author":"Bsteh","year":"2021","journal-title":"Eur J Neurol"},{"key":"2026101308350876000_97.11.992.24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamaneurol.2024.0395","article-title":"High-Efficacy Therapy Discontinuation vs Continuation in Patients 50 Years and Older With Nonactive MS","volume":"81","author":"Jouvenot","year":"2024","journal-title":"JAMA Neurol"},{"key":"2026101308350876000_97.11.992.25","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awv105"},{"key":"2026101308350876000_97.11.992.26","doi-asserted-by":"crossref","DOI":"10.1016\/j.lanepe.2025.101302","article-title":"The Barcelona baseline risk score to predict long-term prognosis after a first demyelinating event: a prospective observational study","volume":"53","author":"Tur","year":"2025","journal-title":"Lancet Reg Health Eur"},{"key":"2026101308350876000_97.11.992.27","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(25)00304-7"},{"key":"2026101308350876000_97.11.992.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.9151"},{"key":"2026101308350876000_97.11.992.29","doi-asserted-by":"crossref","first-page":"e1926","DOI":"10.1212\/WNL.0000000000201029","article-title":"Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis","volume":"99","author":"Roos","year":"2022","journal-title":"Neurology"},{"key":"2026101308350876000_97.11.992.30","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517751049"},{"key":"2026101308350876000_97.11.992.31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaneurol.2023.1542","article-title":"Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation","volume":"80","author":"Zhu","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026101308350876000_97.11.992.32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1212\/WNL.0000000000001706","article-title":"Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS","volume":"85","author":"Kappos","year":"2015","journal-title":"Neurology Jul"},{"key":"2026101308350876000_97.11.992.33","doi-asserted-by":"publisher","DOI":"10.1212\/CPJ.0000000000000800"},{"key":"2026101308350876000_97.11.992.34","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200056","article-title":"Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis","volume":"10","author":"Starvaggi Cucuzza","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026101308350876000_97.11.992.35","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-023-02900-z","article-title":"Extended interval dosing of ocrelizumab modifies the repopulation of B cells without altering the clinical efficacy in multiple sclerosis","volume":"20","author":"Rodriguez-Mogeda","year":"2023","journal-title":"J Neuroinflammation"},{"key":"2026101308350876000_97.11.992.36","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000214473","article-title":"Comparative Effectiveness of Rituximab Dosed Every 6 and 12 Months in Relapsing Multiple Sclerosis","volume":"106","author":"Langer-Gould","year":"2026","journal-title":"Neurology"},{"key":"2026101308350876000_97.11.992.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0268-z"},{"key":"2026101308350876000_97.11.992.38","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac064"},{"key":"2026101308350876000_97.11.992.39","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-330038"},{"key":"2026101308350876000_97.11.992.40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jamaneurol.2022.4655","article-title":"Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple Sclerosis","volume":"80","author":"Tur","year":"2023","journal-title":"JAMA Neurol"},{"key":"2026101308350876000_97.11.992.41","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s40263-023-01038-z","article-title":"Stopping Disease-Modifying Treatments in Multiple Sclerosis: A Systematic Review and Meta-Analysis of Real-World Studies","volume":"37","author":"Prosperini","year":"2023","journal-title":"CNS Drugs"},{"key":"2026101308350876000_97.11.992.42","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00415-022-11341-2","article-title":"Discontinuation of second- versus first-line disease-modifying treatment in middle-aged patients with multiple sclerosis","volume":"270","author":"Chappuis","year":"2023","journal-title":"J Neurol"},{"key":"2026101308350876000_97.11.992.43","doi-asserted-by":"crossref","first-page":"103406","DOI":"10.1016\/j.msard.2021.103406","article-title":"Discontinuation of disease modifying therapies is associated with disability progression regardless of prior stable disease and age","volume":"57","author":"Jakimovski","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"2026101308350876000_97.11.992.44","doi-asserted-by":"crossref","first-page":"105900","DOI":"10.1016\/j.msard.2024.105900","article-title":"The recurrence of disease activity after ocrelizumab discontinuation in multiple sclerosis","volume":"91","author":"Coerver","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"2026101308350876000_97.11.992.45","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10399-8"},{"key":"2026101308350876000_97.11.992.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.101468"},{"key":"2026101308350876000_97.11.992.47","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2025-337944"},{"key":"2026101308350876000_97.11.992.48","doi-asserted-by":"crossref","first-page":"105851","DOI":"10.1016\/j.msard.2024.105851","article-title":"A personalized approach for anti-CD20 therapies in multiple sclerosis","volume":"91","author":"Hogenboom","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"2026101308350876000_97.11.992.49","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200167","article-title":"Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity","volume":"10","author":"Bose","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026101308350876000_97.11.992.50","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","article-title":"Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies","volume":"77","author":"Luna","year":"2020","journal-title":"JAMA Neurol"},{"key":"2026101308350876000_97.11.992.51","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/ene.13181","article-title":"Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis?","volume":"24","author":"Bonenfant","year":"2017","journal-title":"Eur J Neurol"},{"key":"2026101308350876000_97.11.992.52","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s40263-025-01164-w","article-title":"Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study","volume":"39","author":"M\u00fcller","year":"2025","journal-title":"CNS Drugs"},{"key":"2026101308350876000_97.11.992.53","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00027-9"},{"key":"2026101308350876000_97.11.992.54","unstructured":"ClinicalTrials.gov . Disease modifying therapies withdrawal in inactive secondary progressive multiple sclerosis patients older than 50 years (STOP-I-SEP). 2018. Available: https:\/\/clinicaltrials.gov\/study\/NCT03653273"},{"key":"2026101308350876000_97.11.992.55","doi-asserted-by":"crossref","first-page":"105605","DOI":"10.1016\/j.msard.2024.105605","article-title":"Switching from natalizumab to an anti-CD20 monoclonal antibody in relapsing remitting multiple sclerosis: A systematic review","volume":"86","author":"Brown","year":"2024","journal-title":"Mult Scler Relat Disord"},{"key":"2026101308350876000_97.11.992.56","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.13350"},{"key":"2026101308350876000_97.11.992.57","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwv254"},{"key":"2026101308350876000_97.11.992.58","unstructured":"Association. WM . Declaration of Tokyo \u2013 guidelines for physicians concerning torture and other cruel, inhuman or degrading treatment or punishment in relation to detention and imprisonment. Available: https:\/\/www.wma.net\/policies-post\/wma-declaration-of-tokyo-guidelines-for-physicians-concerning-torture-and-other-cruel-inhuman-or-degrading-treatment-or-punishment-in-relation-to-detention-and-imprisonment\/ [Accessed 24 Apr 2024]."},{"key":"2026101308350876000_97.11.992.59","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2026-338694","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T03:00:44Z","timestamp":1791946844000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2026-338694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":59,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,10,13]]},"published-print":{"date-parts":[[2026,11]]}},"alternative-id":["10.1136\/jnnp-2026-338694"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2026-338694","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]}}}